Oral PrEP Drug Truvada, Dapivirine Vaginal Ring Safe, Acceptable HIV Prevention Methods Among Adolescents, Researchers Report At IAS 2017

Healio: Dapivirine vaginal ring safe, acceptable for HIV prevention in teens
“A monthly vaginal ring containing the antiretroviral dapivirine has demonstrated efficacy in girls younger than 18 years, according to phase 2a study results presented at the IAS Conference on HIV Science…” (Bortz, 7/25).

International Business Times: Truvada, Vaginal Rings Can Prevent HIV In Adolescents, Study Says
“…[At] the 9th IAS Conference on HIV Science in Paris, two teams of investigators reported that studies showed a monthly vaginal ring and a daily oral tablet, both containing anti-HIV drugs, were safe for use by adolescents. This research marks the first time medication for the prevention of contracting HIV was specifically tailored and evaluated for adolescents younger than 18 years old, says a statement by the National Institutes of Health (NIH)…” (Anuradha, 7/26).

United Press International: Truvada, vaginal ring safe for HIV prevention in adolescents
“… ‘Adolescents and young people represent a growing share of people living with HIV worldwide,’ Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, said in a press release. ‘Science has demonstrated that the HIV prevention needs of adolescents may be different than those of adults, which is why these new study findings are so important’…” (Wallace, 7/25).

Washington Times: Anti-HIV drugs evaluated in adolescents are safe and acceptable, study shows
“…This was the second clinical trial evaluating oral pre-exposure prophylaxis (PrEP) for the prevention of HIV — marketed as CHAMPS PlusPills but is the PrEP drug Truvada, used in adults but not evaluated for adolescents. The second phase of the clinical trial included study participants from Cape Town and Johannesburg, South Africa. … In a separate study in the U.S., researchers evaluated adherence to and impact of a vaginal ring insert that released PrEP medication into adolescent girls. Scientists recorded high adherence to the ring, adequate levels of the medication in the girls bloodstream, and deemed it safe to the health of the patients…” (Kelly, 7/25).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KFF | twitter.com/kff

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.